Effects of carnitine , ubiquinone and both on the levels of serum Lp(a) and homocysteine and on the oxidative stress in heodialysis patients

INTERVENTION: Control: saline (5cc iv, 3x/week) and lactose (100mg/d, oral) Intervention 1: Intervention: Carnitine (1000mg iv, 3x/week). Intervention 2: Intervention: Ubiquinone (100mg/day, oral). Intervention 3: Intervention: Carnitine (1000mg iv, 3x/week) and ubiquinone (100mg/day, oral). Intervention 4: Control: saline (5cc iv, 3x/week) and lactose (100mg/d, oral). Intervention: Carnitine (1000mg iv, 3x/week) Intervention: Carnitine (1000mg iv, 3x/week) and ubiquinone (100mg/day, oral) Intervention: Ubiquinone (100mg/day, oral) Placebo Treatment ‐ Drugs CONDITION: Chronic renal failure Hemodialysis patients. ; Chronic renal failure PRIMARY OUTCOME: Cardio‐vascular risk factors. Timepoint: Before and after 3 months after intervention. Method of measurement: Serum levels of Lp(a) (Elisa); homocysteine (Enzymatic cycling); and malondialdehyde (spectophotometry). INCLUSION CRITERIA: INCLUSION CRITERIA: 1. Patients under hemodialysis for at least one yer; 2. Serum levels of Lp(a) >20 mg/dl and homocysteine =>15 mg/dl; 3. Willingness to participate and filling up the consent form. Exclusion criteria: 1. Patients with acute or chronic infection; 2. Patients taking carnitine, ubiquinone, vitamins A,E and C during the last month prior to the trial.